Trial Profile
Efficacy and Safety of AP 12009 in Adult Patients with Recurrent or Refractory Anaplastic Astrocytoma (WHO grade III) or Secondary Glioblastoma (WHO grade IV) as Compared to Standard Chemotherapy: A Randomized, Actively Controlled, Open Label Clinical Phase III Study.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 02 Aug 2022
Price :
$35
*
At a glance
- Drugs Trabedersen (Primary) ; Carmustine; Lomustine; Temozolomide
- Indications Anaplastic astrocytoma; Glioblastoma
- Focus Registrational; Therapeutic Use
- Acronyms SAPPHIRE
- Sponsors Isarna Therapeutics
- 30 Jul 2022 This trial has been completed in France (Date of the global end of the trial : 10-Jan-2012), according to European Clinical Trials Database record.
- 06 Jun 2012 New source identified and integrated (German Clinical Trials Register; DRKS00003686).
- 28 Mar 2012 Actual patient number is 27 according to ClinicalTrials.gov.